GRAL: GRAIL, Inc.
About
GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Current Value
$14.981 Year Return
Current Value
$14.981 Year Return
Key Details
Market Cap
$459.22M
P/E Ratio
-0.22
1Y Stock Return
-13.00%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
0.2
Strategies that include GRAL
Stock's related to GRAL
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRBU | 53.51% | $180.20M | -62.45% | 0.00% |
| RUSHA | 51.32% | $4.66B | +53.97% | 1.18% |
| EB | 51.26% | $341.99M | -48.62% | 0.00% |
| PACB | 48.11% | $471.05M | -79.23% | 0.00% |
| CNXN | 47.90% | $1.84B | +14.37% | 0.57% |
| ETD | 46.93% | $740.01M | +7.77% | 5.25% |
| CRSP | 46.73% | $4.01B | -30.49% | 0.00% |
| VCYT | 46.62% | $3.03B | +55.48% | 0.00% |
| ANGO | 46.32% | $273.06M | -0.59% | 0.00% |
| SNDR | 45.83% | $5.41B | +35.80% | 1.22% |
| GWW | 45.68% | $57.08B | +45.28% | 0.68% |
| LASR | 45.38% | $526.43M | -2.60% | 0.00% |
| CDMO | 44.91% | $779.62M | +122.04% | 0.00% |
| LPRO | 44.46% | $738.78M | +2.65% | 0.00% |
| DORM | 44.12% | $4.14B | +89.68% | 0.00% |
| EPAC | 43.37% | $2.55B | +69.58% | 0.09% |
| THR | 42.96% | $1.04B | -1.00% | 0.00% |
| SKLZ | 42.43% | $93.29M | -16.05% | 0.00% |
| ASTE | 42.26% | $820.86M | +13.24% | 1.45% |
| PHR | 42.24% | $1.07B | +20.61% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| INTC | 0.01% | $104.37B | -44.55% | 1.55% |
| BIIB | -0.02% | $22.65B | -32.30% | 0.00% |
| WIX | 0.03% | $10.24B | +90.29% | 0.00% |
| MFC | -0.05% | $57.06B | +70.70% | 3.59% |
| YRD | -0.05% | $518.01M | +101.02% | 3.44% |
| SHLS | -0.06% | $691.80M | -70.53% | 0.00% |
| CLMT | -0.07% | $1.79B | +35.14% | 0.00% |
| CPRX | -0.08% | $2.55B | +55.68% | 0.00% |
| OOMA | -0.11% | $365.28M | +16.00% | 0.00% |
| EGP | 0.12% | $8.62B | +2.17% | 3.00% |
| LILA | -0.13% | $1.37B | +2.95% | 0.00% |
| SHEN | -0.14% | $698.36M | -44.66% | 0.79% |
| ESS | 0.14% | $19.39B | +41.91% | 3.22% |
| CYBR | -0.14% | $13.73B | +64.93% | 0.00% |
| STEP | -0.17% | $4.75B | +155.56% | 1.33% |
| TALO | -0.17% | $1.98B | -20.99% | 0.00% |
| APO | 0.17% | $132.62B | +91.28% | 1.09% |
| MAIN | 0.19% | $4.69B | +33.11% | 5.45% |
| M | 0.20% | $4.20B | +1.20% | 4.56% |
| UDR | -0.20% | $14.68B | +35.67% | 3.83% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SCHW | -22.14% | $142.71B | +43.22% | 1.25% |
| LPLA | -21.17% | $23.55B | +38.13% | 0.38% |
| RJF | -18.43% | $33.06B | +55.96% | 1.11% |
| MNOV | -18.42% | $93.19M | +2.15% | 0.00% |
| MMYT | -18.38% | $11.31B | +142.64% | 0.00% |
| PGR | -16.72% | $149.10B | +57.29% | 0.45% |
| EW | -16.49% | $41.40B | +4.84% | 0.00% |
| VIRT | -15.91% | $3.17B | +110.38% | 2.60% |
| CYD | -15.54% | $364.46M | -2.94% | 4.26% |
| OXBR | -14.85% | $19.05M | +178.18% | 0.00% |
| TEF | -14.29% | $25.59B | +11.27% | 7.19% |
| PCVX | -12.87% | $10.85B | +71.55% | 0.00% |
| VIST | -12.84% | $4.75B | +67.10% | 0.00% |
| AMED | -12.78% | $2.95B | -3.95% | 0.00% |
| SOC | -12.42% | $1.93B | +74.70% | 0.00% |
| GAN | -12.21% | $83.39M | +21.19% | 0.00% |
| TGS | -12.15% | $1.97B | +116.04% | 0.00% |
| CYCN | -10.99% | $4.77M | -16.19% | 0.00% |
| PANW | -10.65% | $126.99B | +46.98% | 0.00% |
| CASI | -10.58% | $71.56M | -6.32% | 0.00% |
ETF's related to GRAL
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ARKG | 47.67% | $1.13B | 0.75% |
| GNOM | 47.29% | $70.59M | 0.5% |
| XRT | 41.97% | $451.85M | 0.35% |
| FBT | 41.70% | $1.11B | 0.56% |
| PBE | 41.69% | $258.53M | 0.58% |
| XTN | 38.88% | $266.48M | 0.35% |
| FIW | 38.58% | $1.86B | 0.53% |
| FXH | 38.39% | $1.15B | 0.62% |
| MOO | 38.35% | $620.40M | 0.53% |
| EDOC | 38.13% | $40.86M | 0.68% |
| ONLN | 37.94% | $89.65M | 0.58% |
| IWM | 37.52% | $75.73B | 0.19% |
| FNX | 37.52% | $1.29B | 0.6% |
| FYX | 37.42% | $959.00M | 0.6% |
| SMDV | 37.39% | $754.57M | 0.4% |
| IBUY | 37.33% | $176.17M | 0.65% |
| MOAT | 37.21% | $15.73B | 0.46% |
| IJR | 37.11% | $90.05B | 0.06% |
| NOBL | 36.99% | $12.44B | 0.35% |
| XAR | 36.99% | $2.56B | 0.35% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SPYG | 0.01% | $32.21B | 0.04% |
| IVW | 0.02% | $54.47B | 0.18% |
| IYW | 0.05% | $19.23B | 0.39% |
| DBMF | 0.13% | $1.02B | 0.85% |
| BCI | -0.24% | $1.20B | 0.26% |
| VUG | -0.24% | $149.28B | 0.04% |
| XLG | -0.26% | $7.40B | 0.2% |
| ARGT | 0.26% | $571.58M | 0.59% |
| TCHP | 0.28% | $890.14M | 0.57% |
| VOOG | -0.30% | $13.96B | 0.1% |
| AGZ | 0.31% | $708.37M | 0.2% |
| IGPT | 0.32% | $407.54M | 0.58% |
| JGRO | -0.34% | $3.98B | 0.44% |
| BSCQ | 0.34% | $4.02B | 0.1% |
| QGRW | 0.46% | $584.66M | 0.28% |
| FLBL | 0.47% | $645.58M | 0.45% |
| XONE | -0.48% | $548.88M | 0.03% |
| USCI | 0.52% | $185.47M | 1.07% |
| WINN | 0.61% | $620.54M | 0.57% |
| SCHG | 0.62% | $35.11B | 0.04% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| USDU | -18.37% | $201.97M | 0.5% |
| WEAT | -17.59% | $120.27M | 0.28% |
| UUP | -15.28% | $309.25M | 0.77% |
| EQLS | -12.92% | $76.08M | 1% |
| BTAL | -12.90% | $388.04M | 1.43% |
| JUCY | -12.20% | $324.29M | 0.6% |
| FLRN | -11.71% | $2.33B | 0.15% |
| DBA | -10.83% | $755.88M | 0.93% |
| FLRT | -10.41% | $401.26M | 0.6% |
| FLOT | -10.22% | $7.31B | 0.15% |
| UNG | -9.96% | $908.80M | 1.06% |
| EPOL | -9.89% | $228.41M | 0.59% |
| JBBB | -9.35% | $1.26B | 0.49% |
| URNM | -8.88% | $1.61B | 0.75% |
| CSHI | -8.66% | $482.85M | 0.38% |
| URNJ | -8.57% | $283.55M | 0.8% |
| BUXX | -8.53% | $162.67M | 0.25% |
| IBDQ | -8.47% | $2.89B | 0.1% |
| SEIX | -8.46% | $268.81M | 0.62% |
| URA | -8.37% | $3.55B | 0.69% |
News
Yahoo
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences.
Yahoo
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca (LSE/STO/Nasdaq:AZN) in collaboration with Daiichi Sankyo (TSE: 4568).
Yahoo
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […]
SeekingAlpha
GRAIL Inc. (NASDAQ:GRAL) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsRobert Ragusa - CEO & DirectorAaron Freidin -...
Yahoo
GRAIL Inc (GRAL) reports a 38% revenue increase and outlines strategic plans for future growth and cost efficiency.
Yahoo
GRAIL ( NASDAQ:GRAL ) Third Quarter 2024 Results Key Financial Results Net loss: US$125.7m (flat on 3Q 2023). US$3.94...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.